Cell Impact (CI) Q1 2026 earnings summary

Executive summary

• Net sales for Q1 2026 increased 16% year-over-year to SEK 2.2 million, mainly from tooling and development projects.

• Operating loss (EBIT) improved to SEK -16.6 million from SEK -20.8 million in Q1 2025, reflecting ongoing cost adaptation.

• Loss after financial items was SEK -18.4 million, with EPS at SEK -0.05 compared to SEK -0.03 last year.

• Rights issue during the quarter was 60% subscribed, raising SEK 23 million before costs.

• Cash and cash equivalents at quarter-end were SEK 4.0 million, declining to SEK 2.8 million by May 12, 2026.

Financial highlights

• Net sales: SEK 2.2 million (Q1 2025: SEK 1.9 million).

• Operating loss (EBIT): SEK -16.6 million (Q1 2025: SEK -20.8 million).

• Loss after tax: SEK -18.5 million (Q1 2025: SEK -21.5 million).

• Cash flow from operating activities: SEK -9.7 million (Q1 2025: SEK -10.8 million).

• Debt/equity ratio: 82% (Q1 2025: 83%).

Outlook and guidance

• Focus remains on expanding business and transitioning to high-volume production.

• Company expects continued dependence on increased cash generation from operations.

• Market uncertainty, especially in Europe, is delaying investment decisions and projects.